[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exosomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exosomes":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,73,95,119,149,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100637502","phase-1-exploratory-study-on-the-efficacy-and-safety-of-nebulized-huc-msc-derived-exosomes-for-non-acute-cip-100637502",false,"NCT07599111","Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP","Exploratory Study on the Efficacy and Safety of Nebulized Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Non-Acute Immune Checkpoint Inhibitor-Related Pneumonitis","Inclusion Criteria:\n\n* Informed consent: Signed written informed consent.\n* Age and diagnosis: Aged 18-75 years with histologically confirmed malignant tumor.\n* Treatment history: Received at least one cycle of immune checkpoint inhibitor therapy and developed immune checkpoint inhibitor-related pneumonitis.\n* Confirmed Grade 3-4 immune checkpoint inhibitor-related pneumonitis (CIP) by clinical evaluation (diagnosis and grading in accordance with the NCCN Guidelines for Management of Immunotherapy-Related Toxicities Version 1.2025), having received standard glucocorticoid therapy for ≥4 weeks, with glucocorticoids either discontinued or tapered to a prednisone-equivalent dose of \\\u003C20 mg\u002Fday.\n* Recent HRCT imaging: Persistent residual CIP-related lesions in both lungs, including ground-glass opacity, consolidation, reticular opacity, traction bronchiectasis, and\u002For honeycombing, involving a large extent of the lung fields; no significant resolution or improvement of these residual lesions on repeated HRCT within the past 4 weeks.\n* General condition: ECOG PS score 0-1, with stable control of the primary tumor for ≥6 months.\n* Contraception: Fertile subjects agree to use effective contraception during the study period and for 360 days after the last dose.\n\nExclusion Criteria:\n\n* Concomitant medication: Current use of antifibrotic agents such as pirfenidone and nintedanib.\n* Operational limitation: Inability to cooperate with pulmonary function testing or nebulized inhalation.\n* History of other pulmonary diseases: Presence of unresolved interstitial lung disease or pulmonary fibrosis induced by targeted therapy, radiotherapy, or other causes.\n* Severe comorbidities: Including severe cardiac, hepatic, or renal insufficiency, or severe hematological abnormalities.\n* Specific medical history: Severe neuromuscular disease, history of organ transplantation, active epilepsy, primary or severe acquired\u002Fsecondary immunodeficiency.\n* Other factors: Severe allergic constitution, psychiatric disorders, use of other investigational products within 28 days, or any other condition deemed inappropriate by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Study Objectives The primary objective of Phase II is to evaluate the percentage of lesion resolution on high-resolution computed tomography (HRCT) as assessed by independent blinded reviewers. Secondary objectives include evaluating effects on pulmonary function, exercise capacity, dyspnea, quality of life, and oxygenation, as well as comprehensively assessing safety and tolerability. Phase I focuses on determining safety, dose-limiting toxicities (DLT), and recommended Phase II dose.\n\nStudy Population\n\nThe target population is patients with non-acute CIP aged 18-75 years with histologically confirmed malignancy. Key inclusion criteria include:\n\nAt least one cycle of immune checkpoint inhibitor (ICI) therapy and development of Grade 3-4 CIP per NCCN Guidelines V1.2025 Standard glucocorticoid treatment for ≥4 weeks, with current dose \\\u003C20 mg\u002Fday prednisone equivalent or discontinued Persistent residual CIP lesions on HRCT without significant improvement in the past 4 weeks ECOG PS 0-1 and stable primary tumor for ≥6 months Effective contraception during the study and for 360 days after last dosing\n\nKey exclusion criteria include:\n\nConcomitant use of pirfenidone, nintedanib, or other antifibrotic agents Inability to perform pulmonary function tests or tolerate nebulization Unresolved interstitial lung disease from radiotherapy or targeted therapy Severe cardiac, hepatic, renal, or hematological dysfunction Organ transplantation, severe immunodeficiency, active epilepsy, or severe allergic status Other investigational drug use within 28 days Study Design and Sample Size Phase I: 9-18 subjects, open-label, dose-escalation design to evaluate DLT and safety Phase II: 40 subjects, randomized, double-blind, placebo-controlled design Study Endpoints Phase I Primary Endpoints Incidence of DLT Incidence of adverse events (AE) and serious adverse events (SAE) Phase II Primary Endpoint Percentage of HRCT lesion resolution at Weeks 4, 12, and 24, assessed by independent blinded reviewers Secondary Endpoints Pulmonary function: FVC%, TLC, RV, FRC, DLCO Functional and symptomatic measures: 6MWD, mMRC dyspnea score, SGRQ, LCQ Oxygenation: PaO₂, A-aDO₂, oxygenation index Exploratory Endpoints Dynamic changes in serum biomarkers: KL-6, cytokines (IL-1β, IL-6, IL-10), immune cell subsets (Tregs, Th1\u002FTh17) Safety Assessments Monitoring of AEs\u002FSAEs graded by CTCAE v5.0 and causality assessment Physical examination, vital signs, SpO₂, 12-lead ECG Laboratory tests: CBC, biochemistry, coagulation, urinalysis, CRP, ESR Study Termination Rules Overall Study Termination Successful completion after all 40 subjects finish 24-week follow-up and database lock Occurrence of unexpected serious or unacceptable safety risks Demonstration of overwhelming efficacy or futility Sponsor termination due to slow enrollment, funding, or major protocol deviations Regulatory or ethics committee requirements Individual Subject Discontinuation Development of DLT or severe hypersensitivity Rapid CIP progression (e.g., \\>50% radiological worsening) Tumor progression or clinical deterioration Withdrawal of informed consent Poor compliance unresponsive to intervention Loss to follow-up or death Investigator judgment of inappropriateness for continued participation Study Timeline Preparation and initiation: January 2026 - May 2026 Phase I\u002FII enrollment: June 2026 - May 2027 Treatment and follow-up (overlapping with enrollment): through June 2028 Database lock and statistical analysis: July 2028 - August 2028 Study closeout: August 2028 - December 2028",[28,29,30,31],"Pneumonitis, Interstitial","Immune Checkpoint Inhibitors (ICIs)","Mesenchymal Stem Cells","Exosomes","NOT_YET_RECRUITING","2026-05-13",{"date":35,"type":36},"2026-05-20","ACTUAL",{"date":38,"type":21},"2026-04",{"date":40,"type":21},"2028-10",{"name":42,"class":43},"Zhou Chengzhi","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100636630","a-randomized-trial-of-intratympanic-drug-delivery-evaluating-the-efficacy-and-safety-of-dexamethasone-loaded-exosomes-versus-standard-therapy-in-acute-sensorineural-hearing-loss-100636630","NCT07568184","A Randomized Trial of Intratympanic Drug Delivery: Evaluating the Efficacy and Safety of Dexamethasone-Loaded Exosomes Versus Standard Therapy in Acute Sensorineural Hearing Loss.","A Phase II, Randomized Trial of Intratympanic Drug Delivery: Evaluating the Efficacy and Safety of Dexamethasone-Loaded Exosomes Versus Standard Therapy in Acute Sensorineural Hearing Loss.","EXO-DEX-SNHL","Inclusion Criteria:\n\n1. Adults aged 18-65 years.\n2. Diagnosis of idiopathic SSNHL (≥30 dB sensorineural loss at three consecutive frequencies) within 14 days of symptom onset.\n3. Failed initial standard systemic steroid therapy (e.g., oral prednisone 1 mg\u002Fkg\u002Fday for 7-14 days) or presented with contraindications to systemic steroids.\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Identifiable cause of hearing loss (e.g., acoustic neuroma, Meniere's disease, trauma).\n2. Pre-existing severe to profound hearing loss in the affected ear.\n3. Active middle ear infection or tympanic membrane perforation.\n4. History of autoimmune disease, coagulation disorders, or immunodeficiency.\n5. Pregnancy or lactation.\n6. Known hypersensitivity to dexamethasone or components of the exosome formulation.\n7. Participation in another interventional clinical trial within 30 days.","65 Years",{"count":54,"type":21},30,[56],"NA","Primary Objective To compare the efficacy of a single course of IT Exo-Dex versus conventional IT dexamethasone and exosome vehicle alone, as measured by the mean change in pure-tone average (PTA; 0.5, 1, 2, 4 kHz) from baseline to the 4-week post-treatment endpoint.\n\nSecondary Objectives\n\n1. To determine the safety and tolerability profile of IT Exo-Dex.\n2. To compare the rate of hearing recovery (defined as \\>10 dB improvement in PTA or recovery to within 10 dB of contralateral ear) among the three treatment groups at 1, 4, and 12 weeks.\n3. To assess changes in auditory function via Auditory Brainstem Response (ABR) thresholds and Otoacoustic Emissions (OAEs).\n4. To characterize the pharmacokinetics and inner ear biodistribution of Exo-Dex using advanced imaging modalities (e.g., MRI with exosome-contrast agents in a sub-study cohort if applicable).",[59,31],"Sensori-Neural Deafness",[61],"Exosomes; SNHL; Dexamethasone","RECRUITING","2026-05-04",{"date":65,"type":36},"2026-05-05",{"date":67,"type":36},"2026-04-03",{"date":69,"type":21},"2027-08",{"name":71,"class":43},"Kafrelsheikh University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":72},"100632849","phase-1-study-of-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-in-vitiligo-100632849","NCT07519031","Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo","A Single-Center, Randomized, Controlled Trial of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Vitiligo","hUMSCs-Exo-VIT","Inclusion Criteria:\n\n* Clinically diagnosed non-segmental vitiligo\n* Progressive vitiligo: new lesions or enlargement of existing lesions within the past 3 months (VIDA score ≥ 3); Stable vitiligo: no new lesions or enlargement of existing lesions within the past 1 year (VIDA score = 0)\n* Total body surface area (BSA) of vitiligo lesions between 1% and 30%\n* Age 18 to 65 years, male or female\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Known allergy to mesenchymal stem cells or exosome components\n* Severe cardiac, hepatic, or renal dysfunction, or severe immunocompromised status\n* For progressive vitiligo: use of systemic immunosuppressants, corticosteroids, phototherapy, or photochemotherapy within the past 3 months\n* For stable vitiligo: use of phototherapy, topical immunosuppressants, or corticosteroids within the past 1 month\n* Concurrent autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, psoriasis) or severe infectious diseases\n* History of malignancy or hematologic disorders\n* History of psychiatric disorders or inability to comply with study procedures\n* Any other condition that, in the investigator's judgment, may increase the risk to the participant or interfere with the conduct of the trial",{"count":82,"type":21},96,[24,25],"This study evaluates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUMSCs-Exo) are safe and effective for treating vitiligo in adults.\n\nVitiligo is a skin condition that causes white patches due to loss of pigment-producing cells. Current treatments have limitations, especially for patients with active disease who require oral steroids with significant side effects.\n\nThis study is a single-center, randomized, controlled trial enrolling 96 adults aged 18 to 65 years with non-segmental vitiligo. Participants are divided into two groups based on disease activity: progressive vitiligo (new patches appearing or existing patches expanding in the past 3 months) and stable vitiligo (no changes in the past year).\n\nFor progressive vitiligo, participants are randomly assigned to either:\n\nExperimental group: hUMSCs-Exo given by intravenous infusion every 2 weeks for 5 sessions, plus tacrolimus ointment and narrowband UVB light therapy, or Control group: oral prednisone (a standard steroid treatment) plus tacrolimus ointment and narrowband UVB light therapy\n\nFor stable vitiligo, participants are randomly assigned to either:\n\nExperimental group: hUMSCs-Exo given by local injection into the white patches every 2 weeks for 5 sessions, plus tacrolimus ointment and narrowband UVB light therapy, or Control group: tacrolimus ointment plus narrowband UVB light therapy alone The treatment period lasts 12 weeks, with follow-up visits continuing to 24 weeks. The main outcome measures include improvement in skin repigmentation measured by the Vitiligo Area Scoring Index (VASI), changes in quality of life, and safety monitoring throughout the study.\n\nThis study aims to establish a standardized approach for using hUMSCs-Exo in vitiligo treatment and to explore how exosomes may work by reducing oxidative stress and regulating immune responses.",[86,30,31],"Vitiligo","2026-04-01",{"date":89,"type":36},"2026-04-09",{"date":38,"type":21},{"date":92,"type":21},"2028-03",{"name":94,"class":43},"Xijing Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":72},"100403253","interest-of-circulating-tumor-dna-in-digestive-and-gynecologicbreast-cancer-100403253","NCT04530890","Interest of Circulating Tumor DNA in Digestive and Gynecologic\u002FBreast Cancer","Inclusion Criteria:\n\n* Digestive or gynecological \u002F breast cancer proven or suspected, requiring oncological treatment (chemotherapy or immunotherapy)\n* Major patient\n* Patients benefiting from a Social Security scheme or benefiting through the intermediary of a third party\n* Information note and collection of non-opposition after clear and fair information about the study\n\nExclusion Criteria:\n\n* Linguistic or psychological refusal or inability to understand and \u002F or sign the information and no-objection note\n* History of a cancer other than that allowing inclusion in the 5 years preceding inclusion",{"count":102,"type":21},1000,[56],"Circulating tumor DNA (ctDNA) offers the possibility of accessing the tumor genome from circulating blood through a simple blood test. It is currently used for diagnostic, prognostic and predictive purposes of response or resistance to oncological treatments. These advances in ctDNA have been made possible by major developments in molecular biology techniques in recent years, as the detection of ctDNA requires very sensitive techniques such as Next Generation Sequencing (NGS).\n\nCtDNA overcomes this problem of very limiting tumor heterogeneity during a solid biopsy. All of these applications make circulating DNA an increasingly essential tool in the management of cancer patients. The studies are currently in most cases on small numbers and are retrospective.\n\nIn addition, exosomes are also a biomarker of the future that can also be detected in the bloodstream . Exosomes are nanovesicles 50 to 200 nm in diameter released into the extracellular environment via the endosomal pathway by fusion with the plasma membrane. They are very informative since they transport tumor genetic material in the form of DNA, mRNA and miRNA, but also adhesion proteins, immunostimulatory molecules and cytoskeleton, enzymes and Heats shock proteins ( HSP).\n\nThe aim of the ADIGYN study is to set up a large prospective cohort to assess the diagnostic, prognostic and predictive impact of ctDNA and exosomes in digestive and gynecological \u002F breast cancers. From the circulating DNA, we characterize the ActDNA on the molecular level thanks to the study of different point mutations usually used but also of new described mutations having a therapeutic impact and the search for other genetic alterations having an impact on the therapeutic strategy (such as microsatellite instability) or the study of exosomes and their composition. To assess resistance to oncological treatments, ctDNA will be analyzed at the start of treatment, during treatment, during progression and \u002F or relapse and also during monitoring or treatment break",[106,107,108,109,31],"Breast Cancer","Digestive Cancer","Gynecologic Cancer","Circulating Tumor DNA","2025-12-17",{"date":112,"type":36},"2025-12-24",{"date":114,"type":36},"2021-03-08",{"date":116,"type":21},"2032-03",{"name":118,"class":43},"Poitiers University Hospital",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":127,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":72},"100487318","exoluminate-study-for-early-detection-of-pancreatic-cancer-100487318","NCT05625529","ExoLuminate Study for Early Detection of Pancreatic Cancer","Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients","Inclusion Criteria:\n\n* ≥18 years old.\n* Meeting criteria for one of the study cohorts.\n* Capable of giving informed consent.\n* Able to provide a blood sample.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old.\n* Pregnancy.\n* Active cancer (other than pancreatic cancer) and\u002For undergoing treatment for an active cancer diagnosis (except for skin malignancies).\n* Prior organ transplant or bone marrow transplant.\n* History of fainting or other adverse effects when blood is drawn.\n* Any condition that, in the opinion of the investigator, should preclude enrollment.",{"count":102,"type":21},"3 Years","OBSERVATIONAL","ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).\n\nThose with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.\n\nThe goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.",[131,31,132,133],"Pancreas Cancer","Extracellular Vesicles","Pancreatic Neoplasms",[135,31,132,136,137,138],"Early Detection","IPMN","PDAC","Pancreatic Cancer","2025-07-24",{"date":141,"type":36},"2025-07-28",{"date":143,"type":36},"2022-12-19",{"date":145,"type":21},"2028-01-01",{"name":147,"class":148},"Biological Dynamics","INDUSTRY",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100570493","prognostic-study-of-via-dynamic-change-of-pca3-mrna-in-drainage-fluid-after-radical-prostatectomy-100570493","NCT06707961","Prognostic Study of Via Dynamic Change of PCA3 mRNA in Drainage Fluid After Radical Prostatectomy","Prognostic Study of Prostate Cancer Via Dynamic Change of PCA3 mRNA in Abdominal Cavity Drainage Fluid After Radical Prostatectomy","Inclusion Criteria:\n\n•Prostate cancer patients treated with radical prostatectomy\n\nExclusion Criteria:\n\n* 1\\. Received neoadjuvant endocrine\u002Fchemotherapy before surgery;\n* 2\\. Urine leakage after surgery (positive creatinine test of drainage fluid).",{"count":157,"type":21},100,"This study investigates the prognostic value of dynamic changes in PCA3 mRNA levels found in the abdominal cavity drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PCA3 mRNA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.",[160,31],"Prostatic Neoplasms","2024-11-26",{"date":163,"type":36},"2024-11-27",{"date":165,"type":21},"2024-12-01",{"date":167,"type":21},"2025-12-01",{"name":169,"class":43},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":177,"sex":16,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":72},"100544382","exosome-micrornas-as-potential-biomarkers-of-metabolic-bone-disease-of-prematurity-100544382","NCT06368154","Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity","Prospective Cohort Study of Exosomal microRNAs as Biomarkers for Diagnosis and Therapeutic Efficacy Evaluation of Metabolic Bone Diseases in Premature Infants","Inclusion Criteria:\n\n* The gestational age was 37+0-41+6 weeks and the age was less than 28 days\n\nExclusion Criteria:\n\n* There was no blood transfusion, no operation, no congenital malformation, no inherited metabolic diseases, no history of intravenous nutrition, and no intestinal diseases",true,"0 Hours","72 Hours",{"count":181,"type":21},200,"Metabolic bone disease of prematurity (MBDP) is caused by insufficient content of calcium, phosphorus, and organic protein matrix in preterm infants or bone metabolism disorder, which is one of the complications affecting the quality of life of preterm infants. The early symptoms of MBDP are insidious, and there is no unified and clear diagnostic method. The diagnosis is mostly based on typical clinical manifestations and X-ray findings, but at this time, bone mineral density has decreased significantly, so early detection and diagnosis are difficult. Studies have shown that exosomal micrornas have biological characteristics and targeting specificity, and can be used as new molecular diagnostic markers for diseases. Several studies have reported the use of plasma or serum microRNAs as molecular markers for early prediction of bone diseases. In our previous study, we extracted plasma exosomes from preterm infants for high-throughput sequencing of microRNAs, and identified differentially expressed micrornas related to bone metabolism. In this study, exosomes were used as carriers, and digital PCR was used to verify the specificity and sensitivity of plasma exosomal microRNA as biomarkers of MBDP in a large sample size. The above biomarkers were compared and verified before and after treatment in children with MBDP. Further revealing plasma exosomal microRNA as a biological indicator for evaluating the efficacy of MBDP may improve the diagnostic level of MBDP, improve the outcome and prognosis of very low birth weight preterm infants, thereby improving global health and reducing socioeconomic costs.",[31,184,185],"Newborn","Bone Diseases, Metabolic","2024-04-15",{"date":188,"type":36},"2024-04-16",{"date":190,"type":36},"2024-01-01",{"date":192,"type":21},"2026-12-31",{"name":194,"class":195},"Hunan Children's Hospital","OTHER_GOV"]